Screener
Celldex Therapeutics CLDX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses | 43,863 | 47,029 |
| Current portion of operating lease liabilities | 1,557 | 1,552 |
| Current portion of other long-term liabilities | 1,230 | 1,230 |
| Total current liabilities | 61,325 | 50,991 |
| Long-term portion of operating lease liabilities | 3,347 | 784 |
| Other long-term liabilities | 3,113 | 4,043 |
| Total liabilities | 67,785 | 55,818 |
| Commitments and contingent liabilities |
Item 1. Unaudited Financial Statements
FAQ
- What is Celldex Therapeutics's total current liabilities?
- Celldex Therapeutics (CLDX) reported total current liabilities of $61.33M in Q2 2026.
- How has Celldex Therapeutics's total current liabilities changed year-over-year?
- Celldex Therapeutics's total current liabilities increased by 86.0% year-over-year, from $32.96M to $61.33M.
- What is the long-term trend for Celldex Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total current liabilities has grown at a 29.1% compound annual growth rate (CAGR), from $14.21M to $50.99M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Celldex Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude